New drug combo aims to boost immune system against advanced cancers
NCT ID NCT05471856
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find the highest safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then every 3 weeks, and ezabenlimab every 3 weeks, for up to 1-2 years if they benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIO Clara Campal
RECRUITINGMadrid, 28050, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Churchill Hospital
RECRUITINGOxford, OX3 7LE, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clinico Universitario De Valencia
RECRUITINGValencia, 46010, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall D Hebron
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Valenciano de Oncología
RECRUITINGValencia, 46009, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Japanese Foundation for Cancer Research
RECRUITINGTokyo, Koto-ku, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGChiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Saitama Medical University International Medical Center
NOT_YET_RECRUITINGSaitama, Hidaka, 350-1298, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital, Chelsea
RECRUITINGLondon, SW3 6JJ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital, Sutton
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University School of Medicine
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.